Hoth Therapeutics Inc (NASDAQ:HOTH) was the target of a large drop in short interest in July. As of July 15th, there was short interest totalling 76,000 shares, a drop of 71.3% from the June 30th total of 265,200 shares. Approximately 0.9% of the shares of the company are short sold. Based on an average trading volume of 690,100 shares, the short-interest ratio is presently 0.1 days.
Separately, Zacks Investment Research lowered Hoth Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday.
In other Hoth Therapeutics news, major shareholder Anthony Hayes sold 400,000 shares of the firm’s stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $1.25, for a total value of $500,000.00. Following the sale, the insider now owns 1,130,674 shares of the company’s stock, valued at approximately $1,413,342.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 17.27% of the stock is currently owned by company insiders.
HOTH opened at $2.73 on Friday. The stock’s 50 day moving average price is $2.69 and its two-hundred day moving average price is $3.52. Hoth Therapeutics has a 12-month low of $2.31 and a 12-month high of $7.25.
Hoth Therapeutics (NASDAQ:HOTH) last announced its quarterly earnings data on Wednesday, May 13th. The company reported ($0.18) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.17) by ($0.01). Research analysts expect that Hoth Therapeutics will post -0.6 EPS for the current fiscal year.
About Hoth Therapeutics
Hoth Therapeutics, Inc, a development stage biopharmaceutical company, focuses on developing targeted therapeutics for atopic dermatitis. It intends to use the BioLexa Platform to develop 2 topical cream products that treat eczema and reduces post-procedure infections for patients undergoing aesthetic dermatology procedures.
Featured Story: Determine Your Level of Risk Tolerance
Receive News & Ratings for Hoth Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hoth Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.